Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Roboz

Showing results (211-220 of 276) with videos related to

Pageof 28
Sort By:
Leukemia|July 1, 2026
Spatial remodeling of bone marrow architecture defines tissue-state signatures of disease activity and therapeutic response in myelodysplastic neoplasmsRyan Nachman, Aleksandra Kopacz, Caitlin Unkenholz, et al.
Leukemia|March 24, 2020
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 studyPau Montesinos, Gail J Roboz, Claude-Eric Bulabois, et al.
Blood Cancer Journal|March 31, 2025
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched studyAlex Bataller, Koji Sasaki, Samuel Urrutia, et al.
The Lancet. Oncology|August 29, 2017
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trialHagop M Kantarjian, Gail J Roboz, Patricia L Kropf, et al.
Archives of Pathology & Laboratory Medicine|March 9, 2025
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/NeoplasmsSavanah D Gisriel, Fnu Aakash, John M Bennett, et al.
Blood Cancer Journal|July 5, 2023
Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999Franck Rapaport, Kenneth Seier, Yaseswini Neelamraju, et al.
Blood|January 14, 2018
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyGerrit J Schuurhuis, Michael Heuser, Sylvie Freeman, et al.
Blood Cancer Journal|September 23, 2022
Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999Franck Rapaport, Kenneth Seier, Yaseswini Neelamraju, et al.
British Journal of Haematology|April 3, 2020
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre settingDiana Hanekamp, Alexander N Snel, Angèle Kelder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2021
Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic SyndromesDavid A Sallman, Amy E DeZern, Guillermo Garcia-Manero, et al.
Pageof 28

Showing results (211-220 of 276) with videos related to

Sort By:
Pageof 28
Leukemia|July 1, 2026
Spatial remodeling of bone marrow architecture defines tissue-state signatures of disease activity and therapeutic response in myelodysplastic neoplasmsRyan Nachman, Aleksandra Kopacz, Caitlin Unkenholz, et al.
Leukemia|March 24, 2020
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 studyPau Montesinos, Gail J Roboz, Claude-Eric Bulabois, et al.
Blood Cancer Journal|March 31, 2025
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched studyAlex Bataller, Koji Sasaki, Samuel Urrutia, et al.
The Lancet. Oncology|August 29, 2017
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trialHagop M Kantarjian, Gail J Roboz, Patricia L Kropf, et al.
Archives of Pathology & Laboratory Medicine|March 9, 2025
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/NeoplasmsSavanah D Gisriel, Fnu Aakash, John M Bennett, et al.
Blood Cancer Journal|July 5, 2023
Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999Franck Rapaport, Kenneth Seier, Yaseswini Neelamraju, et al.
Blood|January 14, 2018
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyGerrit J Schuurhuis, Michael Heuser, Sylvie Freeman, et al.
Blood Cancer Journal|September 23, 2022
Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999Franck Rapaport, Kenneth Seier, Yaseswini Neelamraju, et al.
British Journal of Haematology|April 3, 2020
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre settingDiana Hanekamp, Alexander N Snel, Angèle Kelder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2021
Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic SyndromesDavid A Sallman, Amy E DeZern, Guillermo Garcia-Manero, et al.
Pageof 28